Mera Financial Statements From 2010 to 2025
| MRPI Stock | USD 0.0001 0.00 0.00% |
Check Mera Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mera Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Mera financial statements analysis is a perfect complement when working with Mera Pharmaceuticals Valuation or Volatility modules.
Mera |
Mera Pharmaceuticals Company Current Valuation Analysis
Mera Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Mera Pharmaceuticals Current Valuation | 167.19 K |
Most of Mera Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mera Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Mera Pharmaceuticals has a Current Valuation of 167.19 K. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Mera Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mera Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Mera Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mera Pharmaceuticals competition to find correlations between indicators driving Mera Pharmaceuticals's intrinsic value. More Info.Mera Pharmaceuticals is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Mera Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Mera Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Mera Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as Mera Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Mera Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Mera Pharmaceuticals, Inc. focuses on the development and commercialization of natural products from microalgae using its proprietary and large-scale photobioreactor technology. Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Las Vegas, Nevada. Mera Pharma is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Mera Pink Sheet
Mera Pharmaceuticals financial ratios help investors to determine whether Mera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mera with respect to the benefits of owning Mera Pharmaceuticals security.